[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"amd---age-related-macular-degeneration\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:amd---age-related-macular-degeneration":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,41,65,84,113,138,165,185,223,250],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100585717","visual-rehabilitation-and-depression-in-visually-impaired-patients-with-amd-100585717",false,"NCT06906003","Visual Rehabilitation and Depression in Visually Impaired Patients With AMD","Evaluation of the Impact of Visual Rehabilitation on Anxiety and Depression Severity of Visually Impaired Patients With Advanced Age Related Macular Degeneration","RET 06-24","Inclusion Criteria:\n\n1. Subjects ≥ 55 years\n2. Moderate and severe visual impairment (BCVA ≥1\u002F10 and ≤2\u002F10)\n3. Diagnosis of advanced non-exudative age-related macular degeneration (AMD)\n4. Informed consent freely granted and acquired before the start of the study\n5. Ability to understand and willingness to follow the study instructions and procedures\n\nExclusion Criteria:\n\n1. Visual impairment due to other ocular diseases\n2. Mild visual impairment or partial or total blindness\n3. Exudative age-related macular degeneration undergoing intravitreal drug treatment","ALL","55 Years",{"count":20,"type":21},22,"ESTIMATED","OBSERVATIONAL","Purpose: The aim of this study is to evaluate the impact of visual rehabilitation in visually impaired patients with advanced AMD by the use of questionnaires on the anxiety and depression status.\n\nStudy design: prospective observational study. The study is carried out at the IRCCS Fondazione G.B.Bietti and at the UO Visual Rehabilitation, S. Alessio - Margherita di Savoia.\n\nStudy procedures: Visit 1 (screening visit, at IRCCS Fondazione Bietti) After signing the informed consent, all patients received a complete ophthalmological examination, non-invasive diagnostic tests as optical coherence tomography, autofluorescence and microperimetry, and have to complete the questionnaires on the state of anxiety and depression (GAD-7 and PHQ-9).\n\nVisit 2 (at the Sant'Alessio Institute) for a 60-day visual rehabilitation program scheduled in 5 group meetings.\n\nVisit 3 (end-of-study visit, at IRCCS Fondazione G.B. Bietti) complete ophthalmological examination, as per clinical practice, non-invasive diagnostic tests such as microperimetry, optical coherence tomography and autofluorescence and administration of the Patient Health Questionnaire-9 (PHQ-9) questionnaires for depression and the General Anxiety Disorder (GAD-7) questionnaires for anxiety.",[25,26,27],"AMD - Age-Related Macular Degeneration","Anxiety","Depression Disorders","RECRUITING","2026-05-29",{"date":31,"type":32},"2026-06-01","ACTUAL",{"date":34,"type":32},"2024-12-02",{"date":36,"type":21},"2026-12-02",{"name":38,"class":39},"Fondazione G.B. Bietti, IRCCS","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":62,"leadSponsor":64,"locationsCount":40},"100635592","photobiomodulation-laser-for-reticular-pseudodrusen-in-age-related-macular-degeneration-100635592","NCT07554690","Photobiomodulation Laser for Reticular Pseudodrusen in Age-Related Macular Degeneration","Photobiomodulation Laser in Reticular Pseudodrusen Secondary to Age-related Macular Degeneration","PBM in iAMD","Inclusion Criteria:\n\n* Age ≥ 50 years\n* Diagnosis of reticular pseudodrusen secondary to age-related macular degeneration in the study eye\n* Best-corrected visual acuity (BCVA) between 20\u002F20 and 20\u002F400 (inclusive)\n* Ability and willingness to comply with study procedures and visits\n* Written informed consent obtained prior to any study procedures\n\nExclusion Criteria:\n\n* Presence of geographic atrophy\n* Evidence of macular neovascularization\n* Any previous treatment for age-related macular degeneration, except for antioxidant supplementation\n* Media opacities that may interfere with retinal imaging assessments\n* Use of phototoxic medications (including certain antibiotics or chemotherapeutics) during PBM treatment\n* Any ocular or systemic treatment known to be toxic to the retina or optic nerve\n* History of uveitis (idiopathic or autoimmune)\n* Neovascular glaucoma\n* Glaucoma due to congenital anomalies\n* Glaucoma secondary to active uveitis\n* Any intraocular surgery within 3 months prior to enrollment in the study eye\n* Previous thermal laser treatment in the macular region of the study eye\n* History of vitrectomy, filtering surgery, corneal transplantation, or retinal detachment in the study eye\n* Previous therapeutic radiation to the ocular region or face\n* Women of childbearing potential not using effective contraception during the study treatment period","50 Years",{"count":51,"type":21},67,"INTERVENTIONAL",[54],"NA","This study evaluates whether a low-energy laser treatment called photobiomodulation (PBM) can improve visual function and retinal structure in patients with age-related macular degeneration (AMD) who have reticular pseudodrusen. PBM is a non-invasive therapy that uses specific wavelengths of light to stimulate cellular activity and reduce inflammation without causing tissue damage.\n\nParticipants will be randomly assigned to receive either active PBM treatment or a sham (inactive) treatment. The study will assess changes in visual performance under low-light conditions and retinal structure over a 12-month period.\n\nThe goal is to determine whether PBM can slow disease progression and improve visual function in patients with early stages of AMD.",[25],"NOT_YET_RECRUITING","2026-04-28",{"date":60,"type":32},"2026-05-04",{"date":31,"type":21},{"date":63,"type":21},"2027-12-31",{"name":38,"class":39},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":40},"100625786","prognostic-role-of-macular-neovascular-membrane-subtype-in-pneumatic-displacement-of-macular-hemorrhages-100625786","NCT07427160","Prognostic Role of Macular Neovascular Membrane Subtype in Pneumatic Displacement of Macular Hemorrhages","Inclusion Criteria:\n\n* Patients undergoing pneumatic displacement (PD) for submacular hemorrhage (SMH), secondary to macular neovascularization (MNV)\n* Age 50 years or older at the time of SMH diagnosis\n* Caucasian ethnicity\n* SMH involving the central or internal ring of the Early Treatment Diabetic Retinopathy Study (ETDRS) grid (within a 3 mm circumference centered on the fovea)\n* SMH dimensions equal to or greater than one papillary diameter\n* Pneumatic displacement treatment performed within 36 hours of SMH diagnosis\n\nExclusion Criteria:\n\n* SMH estimated to be present for more than 15 days at the time of diagnosis\n* SMH secondary to conditions other than MNV\n* Presence of proliferative diabetic retinopathy in the study eye\n* Aphakia in the study eye\n* Inadequate pupillary dilation, media opacities, or other impediments to retinal imaging\n* Previous pneumatic displacement procedures for SMH in the study eye\n* Ocular surgery in the 8 weeks preceding the pneumatic displacement intervention\n* Follow-up duration of less than 6 months following the procedure",{"count":72,"type":21},60,"This study investigates the prognostic value of macular neovascularization (MNV) subtypes in patients treated with pneumatic displacement for submacular hemorrhage. The researchers will compare anatomical and functional outcomes (visual acuity) between PCV, RAP, and other MNV forms within a Caucasian cohort to identify subtype-specific predictors of recovery.",[25],"2026-02-17",{"date":77,"type":32},"2026-02-23",{"date":79,"type":32},"2025-10-15",{"date":81,"type":21},"2026-12-15",{"name":83,"class":39},"Marco Mazzola",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":52,"phases":94,"briefSummary":97,"conditions":98,"keywords":99,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":40},"100625095","phase-1-study-in-human-ipscs-derived-rpe-cells-transplantation-for-late-stage-amd-100625095","NCT07418177","Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMD","Study in Human iPSCs-derived Retinal Pigment Epithelium Cells Transplantation for Late-Stage Age-Related Macular Degeneration","Inclusion Criteria:\n\n* (1)Age ≥50 years and ≤80 years, regardless of gender.\n* (2)Patients with atrophic AMD in the macular area (geographic atrophy \\>250μm, involving the foveal center); or stable non-exudative AMD patients who have undergone treatment for wet AMD or have naturally converted to non-exudative AMD (referring to patients with fibrovascular scar formation, who are unresponsive to anti-VEGF treatment, and have no macular edema on OCT and\u002For no fluorescein leakage on FFA), with a scar diameter not exceeding 6 PD.\n* (3)Best-corrected visual acuity (BCVA) of the study eye ≥5 letters and ≤34 letters (using the ETDRS visual acuity chart).\n* (4)If both eyes meet the criteria, the more severely affected eye will be selected; if the severity is the same in both eyes, the right eye will be designated as the study eye.\n* (5)The patient or their legal representative has signed a written informed consent form.\n\nExclusion Criteria:\n\n* Ocular Diseases:\n* (1)Vitreous hemorrhage in the study eye within 2 months prior to screening.\n* (2)Presence of a scar, fibrosis, or atrophy involving the fovea in the study eye, or a peripheral scar area greater than 6 PD, indicating severe irreversible visual loss.\n* (3)Presence of pseudoexfoliation syndrome, central retinal vein occlusion, intraocular hemorrhage causing visual loss, rhegmatogenous retinal detachment, macular hole, or choroidal neovascularization due to any cause in the study eye.\n* (4)Presence of a pupillary block defect (APD) in the study eye.\n* (5)Significant media opacity in the study eye that may interfere with visual function assessment or fundus examination.\n* (6)Acute infectious inflammation in either eye during the screening period.\n* (7)Patients with intraocular pressure higher than 25 mmHg despite medical treatment.\n* (8)Monocular blind patients.\n\nOcular Treatments:\n\n* (9)The study eye has undergone focal\u002Fgrid laser photocoagulation within 3 months prior to screening.\n* (10)The study eye has undergone the following intraocular surgeries or laser treatments within 3 months prior to screening, such as macular translocation, cataract surgery, glaucoma filtration surgery, verteporfin photodynamic therapy, transpupillary thermotherapy, foveal laser photocoagulation, vitrectomy, optic nerve decompression, or optic nerve sheath decompression.\n* (11)Any eye has received anti-angiogenic drug treatment (including any anti-VEGF drugs) within 3 months prior to screening (e.g., Aflibercept \\[Eylea®\\], Ranibizumab \\[Lucentis®\\], Bevacizumab \\[Avastin®\\]).\n\nSystemic Diseases, Treatments, and Other Conditions:\n\n* (12)Patients with an allergic reaction or history of allergy to sodium fluorescein and indocyanine green, a history of allergy to protein products used for treatment or diagnosis, and patients with allergies to two or more drugs and\u002For non-drug factors, or those currently suffering from allergic diseases.\n* (13)Patients with uncontrolled diabetes (fasting blood glucose ≥7.0 mmol\u002FL or 2-hour postprandial blood glucose ≥11.1 mmol\u002FL).\n* (14)Patients with a history of surgical procedures within 1 month prior to screening, or those with unhealed wounds, ulcers, fractures, etc.\n* (15)Patients with uncontrolled hypertension (defined as a single measurement of systolic blood pressure \\>180 mmHg, two consecutive measurements of systolic blood pressure \\>160 mmHg, or diastolic blood pressure \\>100 mmHg despite optimal treatment).\n* (16)Patients with a history of myocardial infarction within 6 months prior to enrollment.\n* (17)Patients with active disseminated intravascular coagulation or a significant tendency to bleed; patients who have used anticoagulant or antiplatelet aggregation drugs within 14 days prior to screening, except for aspirin\u002Fnonsteroidal anti-inflammatory drugs.\n* (18)Patients with any uncontrollable clinical issues (such as severe psychiatric, neurological, cardiovascular, respiratory, malignant tumors, Parkinson's disease, Alzheimer's disease, and other systemic diseases).\n* (19)Women of childbearing age with a positive pregnancy test during the screening period. Women who wish to breastfeed during the study period, and all patients of childbearing age (male and female) who do not agree to take effective contraceptive measures (such as intrauterine devices, oral contraceptives, or condoms) throughout the study period and for 30 days after the end of the visit period.\n* (20)Patients who have participated in or are currently participating in other clinical studies within 30 days prior to screening.\n* (21)Hemoglobin \\\u003C100 g\u002FL, platelets ≤100×109\u002FL, neutrophil count \\\u003C1.0×109\u002FL, ALT\u002FAST \\>1.5×upper limit of normal (ULN), creatinine \\>1.3 mg\u002FdL.\n* (22)Patients deemed unsuitable for inclusion by the investigator, or other medical conditions that limit the subject's compliance, safety, or affect the results of the study trial.","80 Years",{"count":93,"type":21},9,[95,96],"PHASE1","PHASE2","Phase I Study of the Safety and Preliminary Efficacy of Human induced pluripotent stem cells-derived Retinal Pigment Epithelial (HiPSC-RPE) Cells Subretinal Transplantation in Late-Stage Age-Related Macular Degeneration(AMD) Patients",[25],[100,101,102,103],"Late-Stage Age-related Macular Degeneration","Age-Related Macular Degeneration","Macular Degeneration","AMD","2026-02-11",{"date":106,"type":32},"2026-02-18",{"date":108,"type":21},"2026-02-10",{"date":110,"type":21},"2028-12-31",{"name":112,"class":39},"The First Affiliated Hospital with Nanjing Medical University",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":52,"phases":122,"briefSummary":123,"conditions":124,"keywords":125,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":40},"100624419","repeated-low-level-red-light-therapy-in-dry-age-related-macular-degeneration-100624419","NCT07409389","Repeated Low-Level Red-Light Therapy in Dry Age-Related Macular Degeneration","Safety and Efficacy of Repeated Low-Level Red-Light Therapy in Dry Age-Related Macular Degeneration: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 50 years old.\n2. Diagnosis of dry AMD in Age-Related Eye Disease Study (AREDS) category 2 to 4, as determined by color fundus photography and fundus autofluorescence imaging. The AREDS categories will be defined as follows:\n\n   i) AREDS category 2 (early AMD): Multiple small drusen, a few intermediate drusen (63-124 μm in diameter), or retinal pigment epithelium (RPE) abnormalities ii) AREDS category 3 (intermediate AMD): Extensive intermediate drusen, including at least one large drusen (\\> 125 μm in diameter), or geographic atrophy (GA) not involving the center of the fovea.\n\n   iii) AREDS category 4 (advanced\u002Flate AMD): GA involving the center of the macula.\n\n   If both eyes meet the inclusion criteria, both eyes will be included in the study analysis.\n3. ETDRS BCVA score between 50 and 75 (Snellen equivalent of 20\u002F32 to 20\u002F100). Willingness to provide written informed consent after being informed of the nature of the study.\n\nExclusion Criteria:\n\n1. Previous or active neovascular maculopathy.\n2. Presence of center involving GA within the central 500 μm of the ETDRS grid.\n3. Ocular disease other than dry AMD that could cause drusen (glomerulonephritis Type 2, Autosomal dominant drusen), GA (North Carolina macular dystrophy), or mitochondrial disorders (parafoveal petaloid GA, Stargardt disease).\n4. Invasive eye surgery (e.g. cataract extraction, capsulotomy) within 3 months.\n5. Cognitive impairment or history of epilepsy.\n6. Other significant ocular disease affecting visual acuity (e.g., diabetic macular edema, uncontrolled glaucoma, active uveitis, vitreoretinal disease, intraocular tumor, retinal vascular disease, lens opacities more severe than C2, N2, P2 \\[LOCS III\\]).\n\nAfterimage \\> 5 min (contraindication of red-light therapy).",{"count":121,"type":21},94,[54],"This prospective, double-blind, randomized controlled trial aims to evaluate the efficacy and safety of repeated low-level red-light (RLRL) therapy in patients with dry age-related macular degeneration (AMD). The primary objective is to assess the effect of RLRL therapy on visual function in patients with dry AMD, while the secondary objective is to evaluate its safety and tolerability.\n\nSeventy-four participants aged 50 years or older with dry AMD will be enrolled and randomly assigned in a 1:1 ratio to either the active RLRL intervention group (using the full device power) or the control group (sham device at 10% power). Group assignments will be masked to both participants and investigators. Participants will administer the treatment at home twice daily (3-minute sessions, with at least a 4-hour interval between sessions) over five consecutive weekdays each month for three months. A video tutorial will guide device usage, with ongoing support from the research team.\n\nBefore enrollment, participants will undergo a comprehensive assessment, including ocular and family history review, OCT, and fundus photography to confirm eligibility. Evaluations will occur at baseline, 1 month, and 3 months, covering best-corrected visual acuity (BCVA), slit-lamp examination, OCT, OCT angiography (OCTA), fundus autofluorescence (FAF), contrast sensitivity, color vision, electroretinography (ERG), visual-related quality of life (VRQL) questionnaires, and adverse event monitoring.\n\nThe primary outcome is the mean change in BCVA from baseline to 3 months. Secondary outcomes include changes in central drusen thickness, geographic atrophy (GA) size and progression, choroidal blood flow, contrast sensitivity, ERG responses, and VRQL scores.\n\nGiven the limited treatment options for dry AMD, which are primarily focused on lifestyle changes and nutritional supplements, this study investigates the potential of RLRL therapy as a novel, non-invasive treatment. The results may address the unmet medical need in dry AMD, potentially slowing disease progression and improving patients' quality of life.",[25],[126,127,128],"Dry Age-Related Macular Degeneration","Red light therapy","Visual function","2026-02-06",{"date":131,"type":32},"2026-02-13",{"date":133,"type":21},"2026-01-26",{"date":135,"type":21},"2026-12-01",{"name":137,"class":39},"The Hong Kong Polytechnic University",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":145,"sex":17,"minAge":146,"maxAge":49,"enrollmentInfo":147,"targetDuration":4,"studyType":52,"phases":149,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":40},"100618365","phase-1-a-phase-1-study-of-abf-101-in-single--and-multiple-ascending-doses-100618365","NCT07330674","A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses","A Phase 1, Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, and Pharmacokinetics of Orally Administered ABF- 101","Inclusion Criteria:\n\n* Part A and B\n\n  1. Healthy participants, aged between 18 and 50 years\n  2. Provides written, signed, informed consent prior to selection\n  3. BMI of ≥ 18.0 and \\\u003C 32.0 kg\u002Fm2, and body weight between 50 kg and 115 kg, inclusive.\n  4. Vital signs: normal pulse rate and blood pressure.\n  5. Nonsmoker\n  6. Must be willing to abstain from caffeine and alcohol\n  7. Must be willing to avoid strenuous activity\n* Part C\n\n  1. Confirmed diagnosis of AMD\n  2. Male or female ≥50 years of age\n  3. Adequate visual acuity in the non-study eye\n\nExclusion Criteria:\n\n* Part A and B\n\n  1. Any history or presence of cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic, or infectious disease\n  2. Any significant abnormalities detected during ocular examination,\n  3. Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician\n  4. Any drug intake (except paracetamol or contraceptives)\n  5. History or presence alcohol abuse\n  6. History or presence of drug abuse\n  7. Positive HBsAg or anti-HCV antibody, or positive results for HIV\n  8. Blood donation, significant blood loss, or has received a transfusion of any blood or blood products\n  9. Female participants who are breastfeeding.\n  10. Female participants must not be pregnant or at risk to become pregnant during the study. Male and female participants must agree to use highly effective contraception\n  11. Participant who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language barrier or poor mental development\n\nPart C\n\n1. Evidence of CNV due to any cause other than AMD\n2. History of vitreoretinal surgery\n3. Significant ocular diseases that may interfere with the study\n4. Significantly impaired renal or hepatic function\n5. Use of immunosuppressive drugs\n6. Use of any investigational agent or participation in any other clinical trial of an investigational agent or investigational therapy\n7. History of severe drug allergies or drug hypersensitivity syndrome\n8. Undiagnosed acute illness first observed during screening or between screening and baseline, or severe concurrent medical conditions that, in the investigator's judgment, represent a safety concern.\n9. Severe cardiac disease.\n10. QTc ≥450 msec or participants with a history of risk factors or other clinically significant ECG abnormalities\n11. Stroke or transient ischemic attack\n12. Any major surgical procedure w\n13. Serious active infection, other serious medical condition or any other condition that would impair the ability of the participant to administer the investigational drug or to adhere to the study protocol requirements\n14. Presence of any condition which, in the judgment of the investigator, would prevent the participant from completing the study",true,"18 Years",{"count":148,"type":21},68,[95],"This is a Phase 1 study to evaluate the safety, tolerability, PK, and PD of ABF-101 in healthy participants and participants with age-related macular degeneration (AMD).",[152,25],"Age Related Macular Degeneration (ARMD)",[154,103,155],"ABF-101","NOX","2026-02-04",{"date":129,"type":32},{"date":159,"type":21},"2026-02",{"date":161,"type":21},"2027-12",{"name":163,"class":164},"Aptabio Therapeutics, Inc.","INDIV",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":40},"100603977","comparison-of-the-sensibility-of-swept-source-optical-coherence-tomography-devices-in-the-detection-of-neovascularisation-in-large-pigment-epithelium-detachments-100603977","NCT07143526","Comparison of the Sensibility of Swept Source Optical Coherence Tomography Devices in the Detection of Neovascularisation in Large Pigment Epithelium Detachments","Comparison of Two Swept-source Optical Coherence Tomography Angiography (OCTA) Devices (Bmizar and Plexelite) for Detecting Macular Neovascularisation With Large (More Than 250 Microns) Pigment Epithelium Detachment (PED) in Age Related Macular Degeneration","Inclusion Criteria:\n\n* Patients treated for neovascular age related macular degeneration (AMD)\n* Presence of a pigmentary epithelium detachment higher than 250 microns measured on structural optical coherence tomography (OCT)\n\nExclusion Criteria:\n\n* Poor image quality or signal strength\n* Undefined retina layers",{"count":173,"type":21},50,"The goal of this observational study is to compare swept source optical coherence tomography devices ability to detect macular neovascularisation when there is a large pigment epithelium detachment higher than 250 microns",[25],"2025-08-19",{"date":178,"type":32},"2025-08-27",{"date":180,"type":21},"2025-08",{"date":182,"type":21},"2025-09",{"name":184,"class":39},"University of Trieste",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":145,"sex":17,"minAge":193,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":196,"conditions":197,"keywords":206,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":40},"100603365","my-eyes-my-light-amar-chokh-amar-alo-100603365","NCT07135570","\"My Eyes, My Light\": Amar Chokh, Amar Alo","Stop Blindness in Coastal Bangladesh: Testing the Effectiveness of Community-Based, Artificial Intelligence-Assisted Eye Disease Screening in Coastal Bangladesh","ACA2","Inclusion Criteria:\n\n* Age 35+ years\n* Residing in the Sub-District of Char Fasson in the Bhola District\n\nExclusion Criteria:\n\n* Known eye disease diagnosis","35 Years",{"count":195,"type":21},20000,"Eye disease affects 2.2 billion people globally, which in turn adversely affects schooling, economic productivity, and participation in social life. The primary conditions contributing to visual impairment and blindness include cataracts, age-related macular degeneration (AMD), glaucoma, diabetic retinopathy (DR), refractive error, and presbyopia. Early detection of eye disease can provide substantial benefits in prompting treatment to reduce progression and mitigate disability.\n\nCompared with other regions, South Asia has the most cases of visual impairment due to cataracts and uncorrected refractive error. The combination of poverty, poor living and working environments, and limited health care access have long endangered eye health in Bangladesh. Coastal Bangladesh is particularly impacted by eye disease due to economic deprivation and limited healthcare access. The coastal population mostly works in fishing and agriculture, have prolonged sunlight exposure, and inadequate occupational eye protection. This low-lying region, with 35 million people, is especially vulnerable to climate disasters and global warming. High rates of chronic disease, especially diabetes mellitus Type 2 and hypertension, coupled with limited screening and treatment, shape the area's health profile, with the increasing prevalence of eye diseases such as DR, glaucoma, and visual impairment.\n\nTo address the issues of poor health, accessibility, and affordability of eye care, Artificial Intelligence (AI) applications, such as Artificial Intelligence (AI)-assisted fundus imaging, can be applied in eye screening. Medical AI applications have the potential to improve the quality and efficiency of healthcare, reduce healthcare costs, optimize treatment plans, and bolster the development of primary healthcare. They can identify presumptive DR, hypertensive retinopathy (HR), AMD, and glaucoma by analyzing the retina and optic disc of fundus images with moderate accuracy and high efficiency, thus helping address the lack of local eye care professionals.\n\nData Yakka developed a human-AI collaboration that delivers affordable and transformative community-based eye screening to underserved communities in the coastal Bangladesh region of Char Fasson. The \"Amar Chokh Amar Alo\" (My Eyes, My Light) initiative creates and implements comprehensive eye screening that combines AI-assisted eye screening and grassroots partnerships with trusted non-health non-governmental organizations (NGOs). It has three objectives: 1) Enhancing accessibility and affordability of eye screening; 2) Supporting high quality and efficient treatment of those problems detected via screening, 3) Collecting fundus images to refine or train AI algorithms in the future. This project was designed to evaluate the feasibility, performance, equity, and cost of this model of eye screening and its implications for global eye disease.\n\nThe implementation of participant recruitment, data collection, screening, and follow-up was separated into twelve steps. This standardized framework ensured the integration of screening with data collection and follow-up eye care services. Based on risk stratification by diabetes, hypertension, age 50+ years, and\u002For optometrist recommendation, fundus imaging was offered selectively to higher-risk patients.",[198,199,200,201,25,202,203,204,205],"Glaucoma","Diabetic Retinopathy (DR)","Hypertensive Retinopathy","Cataract","Presbyopia","Myopia","Hyperopia","Dacryocystitis",[207,208,209,210,211,212,213],"vision care","eye disease screening","cataracts","glaucoma","age-related macular degeneration","refractive error","Bangladesh",{"date":215,"type":32},"2025-08-22",{"date":217,"type":32},"2025-01-05",{"date":219,"type":21},"2026-06",{"name":221,"class":222},"Data Yakka, Inc.","INDUSTRY",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":145,"sex":17,"minAge":231,"maxAge":232,"enrollmentInfo":233,"targetDuration":235,"studyType":22,"phases":4,"briefSummary":236,"conditions":237,"keywords":238,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":40},"100597569","the-impact-of-artificial-lighting-on-the-visual-capacity-of-patients-with-age-related-macular-degeneration-100597569","NCT07060196","The Impact of Artificial Lighting on the Visual Capacity of Patients With Age-Related Macular Degeneration","The Impact of Artificial Lighting on the Visual Capacity of Patients With Age-Related Macular Degeneration.","ADLs AMD","Inclusion Criteria:\n\n* Healthy controls over the age of 60.\n* Diagnosis of bilateral dry age-related macular degeneration (AMD).\n\nExclusion Criteria:\n\n* Patients with other ocular conditions such as high myopia, glaucoma, clinically significant diabetic retinopathy, and other diseases that may confound the evaluation of ocular outcome measurements.\n* Patients who have undergone intraocular surgeries, except for uncomplicated cataract extraction surgery performed at least 3 months prior to their inclusion in the study.\n* Individuals with systemic diseases, including oxalate kidney stones, Wilson's disease, hemochromatosis, lung cancer, or other illnesses associated with poor five-year survival.\n* Patients with binocular best-corrected distance visual acuity less than or equal to hand motion perception.\n* Patients with neurological, orthopedic, or psychiatric disorders that prevent them from completing the activities or conditions that may affect their performance.","60 Years","100 Years",{"count":234,"type":21},70,"15 Days","Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in the elderly worldwide. The dry, non-exudative form of the disease, although more common, is associated with gradual and significant decline in functional vision. Despite advancements in diagnostic and therapeutic approaches, a targeted intervention that improves the daily functionality of these patients is still lacking. One critical, yet often overlooked, factor that affects daily performance is lighting conditions.\n\nThis study aims to objectively assess the impact of different lighting intensity levels on patients with advanced dry AMD during the execution of everyday activities. A total of 60 individuals will be evaluated (30 healthy controls over 60 years of age and 30 patients with clinically diagnosed advanced AMD, according to NICE and AREDS criteria). Participants will undergo ophthalmological assessment (visual acuity, contrast sensitivity, OCT\u002FOCTA, autofluorescence), and their performance on five functional tasks (mobility, object grasping, sit-to-stand transition, obstacle avoidance, and hanging clothes) will be evaluated under eight lighting levels (20-300 lux) at a constant color temperature (4000K), in a specially designed laboratory equipped with motion and eye-tracking systems.\n\nThe primary endpoint is overall performance, based on task completion time and errors, expressed on a custom performance scale (0-100). Secondary data include changes in pupil size as an indicator of visual adaptation. The study aims to determine the optimal lighting range that maximizes functional vision and improves the quality of life for patients with AMD.",[25],[103,239,240],"artificial lighting","ADLs","2025-07-08",{"date":243,"type":32},"2025-07-11",{"date":245,"type":21},"2025-06-30",{"date":247,"type":21},"2027-01-31",{"name":249,"class":39},"Democritus University of Thrace",{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":145,"sex":17,"minAge":146,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":52,"phases":259,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":4},"100581118","retinal-investigation-using-optos-oct-device-100581118","NCT06846151","Retinal Investigation Using Optos OCT Device","Clinical Investigation of Optos OCT in Patients with Retinal Pathologies","Inclusion Criteria:\n\n1. Male or female participants 18 years of age or older who have full legal capacity to volunteer on the date the informed consent is signed.\n2. Participants who understand the study and patient information sheet and can follow the instructions.\n3. Participants who agree to participate in the study.\n4. Control group where no retinal abnormalities were detected as part of the standard basic ophthalmic examination.\n5. Participants with retinal disease in at least one eye including: Early dry age-related macular degeneration, late stage dry age-related macular degeneration specifically geographic atrophy, Wet age-related macular degeneration, Retinitis pigmentosa, Diabetic retinopathy and other macular atrophic diseases\n\nExclusion Criteria:\n\n1. Inability to understand written and verbal English sufficiently to comprehend the study and provide informed consent\n2. Ophthalmic disease other than condition under investigation.\n3. Participants unable to tolerate ophthalmic imaging.\n4. Cataract (unless deemed mild in the opinion of the investigator)\n5. Participants with significant ocular media not sufficiently clear to obtain acceptable OCT images.\n6. Diabetes (unless part of the diabetic eye disease group)\n7. Binocular visual acuity worse than 6\u002F18\n8. Strabismus (squint)\n9. Age related macular degeneration groups: polypoidal choroidal vasculopathy\n10. Participants with photo sensitivity epilepsy, experience of seizures, or sensitivity to flickering light (based on self-report)\n11. Pregnant",{"count":258,"type":21},120,[54],"Retinal investigation using OCT with control and diseased eyes",[25,262,263,264],"Retinitis Pigmentosa (RP)","Diabetic Retinopathy","Control Patients","2025-02-20",{"date":267,"type":32},"2025-02-25",{"date":269,"type":21},"2025-05",{"date":271,"type":21},"2026-01",{"name":273,"class":222},"Optos, PLC"]